You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Amgen Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Amgen Company Info
One of the pioneers of the biotech industry, Amgen is now one of the world's largest pharmaceutical companies, with more than a dozen products focused on cancer, inflammation, neurology, cardiology, and more.
News & Analysis
These are stocks all income investors should consider buying and holding.
Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.
Amgen's stock has held up much better than the S&P 500 index.
The company finds some protection against measures aimed to cut industry drug prices.
A new tax could steer big companies toward paying higher dividends.
Both companies have outperformed the market over the past few decades.
These two dividend-paying pharmaceutical titans ought to keep crushing the broader markets for the foreseeable future.
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Its size, catalog, and pipeline give it strengths that are hard to beat.
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.
AMGN earnings call for the period ending October 31, 2021.
AMGN earnings call for the period ending June 30, 2021.
AMGN earnings call for the period ending March 31, 2021.
AMGN earnings call for the period ending December 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.